tiprankstipranks
BeOne Medicines (ONC)
NASDAQ:ONC
US Market
ONC
BeOne Medicines
RESEARCH TOOLSreports
Want to see ONC full AI Analyst Report?

BeOne Medicines (ONC) Stock News & Sentiment

860 Followers
Buy Rating on BeOne Medicines: Strong Brukinsa Positioning, Deep Oncology Pipeline, and Attractive Valuation Ahead of 2026 Milestones
Premium
Ratings
Buy Rating on BeOne Medicines: Strong Brukinsa Positioning, Deep Oncology Pipeline, and Attractive Valuation Ahead of 2026 Milestones
1M ago
ONC
BeOne Medicines Advances Combo Cancer Pill With Completed Phase 1 Bioavailability Study
Premium
Company Announcements
BeOne Medicines Advances Combo Cancer Pill With Completed Phase 1 Bioavailability Study
1M ago
ONC
BeOne Medicines Advances BG-A3004 Into First-in-Human Skin Disease Trial: What Investors Should Watch
Premium
Company Announcements
BeOne Medicines Advances BG-A3004 Into First-in-Human Skin Disease Trial: What Investors Should Watch
1M ago
ONC
Early Cancer Drug Trial Termination Highlights Pipeline Risk for BeOne Medicines (ONC)
Premium
Company Announcements
Early Cancer Drug Trial Termination Highlights Pipeline Risk for BeOne Medicines (ONC)
1M ago
ONC
BeiGene Terminates Early-Stage Solid Tumor Trial, Shifting Risk Focus for Oncology Investors
Premium
Company Announcements
BeiGene Terminates Early-Stage Solid Tumor Trial, Shifting Risk Focus for Oncology Investors
1M ago
ONC
Beigene, Ltd. (ONC) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
Beigene, Ltd. (ONC) Q4 Earnings Cheat Sheet
2M ago
ONC
Zanubrutinib Update: What BeiGene’s BTK Intolerance Study Means for Oncology Investors
Premium
Company Announcements
Zanubrutinib Update: What BeiGene’s BTK Intolerance Study Means for Oncology Investors
3M ago
ONC
More ONC News >

ONC News on the Web

BeiGene (ONC) Prepares for Q1 Earnings Announcement with Strong Track Record
GuruFocus News
Neutral
BeOne Medicines (ONC) Receives Conditional Approval for Lung Cancer Treatment
GuruFocus News
Bullish
BeOne Medicines (ONC) Receives a Buy from Truist Financial
TipRanks News
Bullish
RBC Capital Keeps Their Buy Rating on BeOne Medicines (ONC)
TipRanks News
Bullish
BeOne Medicines price target lowered to $411 from $412 at Truist
TipRanks News
Neutral
Truist Financial Remains a Buy on BeOne Medicines (ONC)
TipRanks News
Neutral
Baker Bros. Advisors LP Increases Stake in Celcuity Inc.
GuruFocus News
Neutral
Buy Rating on BeOne Medicines: Strong Brukinsa Positioning, Deep Oncology Pipeline, and Attractive Valuation Ahead of 2026 Milestones
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
ONC
Sector Average
Media Buzz
Currently, no data available
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is ONC’s Media Buzz Sentiment?
Currently, no data Available
What is ONC’s weekly average amount of articles?
Currently, no data Available
What is ONC’s News Sentiment?
Currently, no data Available
Healthcare Stocks that are Trending in the News
TVTXTravere Therapeutics
HVOOpen Orphan Plc
PBMPsyence Biomedical
QDELQuidelOrtho
Showing the stocks with the most bullish news sentiment over the past week